Jan 30 |
Baillie Gifford Bolsters Stake in Nanobiotix SA
|
Jan 29 |
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
|
Dec 26 |
Johnson & Johnson inks licensing deal with LianBio (update)
|
Dec 26 |
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
|
Dec 13 |
Voting Rights and Shares Capital of the Company
|
Dec 4 |
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
|
Nov 14 |
Nanobiotix S.A. (NBTX) Q3 2023 Earnings Call Transcript
|
Nov 14 |
Nanobiotix S.A. 2023 Q3 - Results - Earnings Call Presentation
|
Nov 13 |
Nanobiotix reports Q3 results
|
Nov 13 |
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
|